Zea Mays L.ÀÇ ºÒ°ËÈ Á¤·®ÃßÃâ¹°(DENTADOL¢ç)ÀÌ ¿Ü°úÀû Ä¡ÁÖÄ¡·áÈÄÀÇ Ä¡À¯¿¡ ¹ÌÄ¡´Â È¿°ú¿¡ °üÇÑ ÀÓ»óÀû ¿¬±¸
Clinical trial of unsaponifiable fraction of zea mays L. on healing after surgical periodontal therapy in human
ÃÖ»ó¹¬, ÇѼöºÎ, Ȳ±¤¼¼,
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖ»ó¹¬ ( Choi Sang-Mook ) - ¼¿ï´ëÇб³ Ä¡°ú´ëÇÐ Ä¡ÁÖ°úÇб³½Ç
ÇѼöºÎ ( Han Soo-Boo ) - ¼¿ï´ëÇб³ Ä¡°ú´ëÇÐ Ä¡ÁÖ°úÇб³½Ç
Ȳ±¤¼¼ ( Hwang Kwang-Sei ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ Ä¡ÁÖ°úÇб³½Ç
KMID : 0363019890190010063
Abstract
The efficacy of unsaponifiable fraction of Zea Mays L compared with placebo was evaluated by a double blind method. Subjects were 57 SNUDH out-patients undergoing the Modified Widman flap surgery. The subjects were divided randomly into 2 groups ; 36 subjects were given sugar -coated tablets containing 35mg active drug and 21 were given only placebo sugar-coated tablets. To evaluate the effect, we used a gingival index, pocket depth measurement, a tooth mobility index and the rate of lamina dura appearance. The subjects were evaluated before surgery, 2 weeks, 4 weeks, 8 weeks and 12 weeks after surgery. Zea Mays L seemed to play a significant role in the reduction of gingival inflammation after surgery and was superior to placebo in all parameters and had little adverse effect.
Å°¿öµå
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸